Table 2.
Adverse events at least possibly related to study treatment. All Grade 4 or 5 adverse events, as well as common (≥5% of patients) Grade 3 events are included.
| Associated with VR-CHOP n (%) of eligible patients (total n = 65) | Associated with bortezomib maintenance n (%) of eligible patients (total n = 47) | |||||
|---|---|---|---|---|---|---|
| Adverse Event (grade ≥3) | Grade 3 | Grade 4 | Grade 5 | Grade 3 | Grade 4 | Grade 5 |
| Hematologic/infection | ||||||
| Neutropenia | 9 (14) | 25 (38) | - | - | - | - |
| Febrile neutropenia | 11 (17) | 1 (2) | - | - | - | - |
| Thrombocytopenia | 5 (8) | 6 (9) | - | - | - | - |
| Anemia | 3 (5) | - | - | - | - | - |
| Lymphopenia | 11 (17) | 4 (6) | - | 1 (2) | 1 (2) | - |
| Leukopenia | 16 (25) | 10 (15) | - | - | - | - |
| Lung infection | 4 (6) | - | - | 1 (2) | - | - |
| Cardiovascular | - | - | 1 (2) | - | - | - |
| Diarrhea | 3 (5) | - | - | - | - | - |
| Fatigue | 4 (6) | 2 (3) | - | 1 (2) | - | - |
| Hyperglycemia | 3 (5) | - | - | - | - | - |
| Hyperuricemia | - | 1 (2) | - | - | - | - |
| Sensory neuropathy | 3 (5) | - | - | 1 (2) | - | - |